CN107614531A - 在造血和淋巴恶性肿瘤中靶向cd99的组合物和方法 - Google Patents

在造血和淋巴恶性肿瘤中靶向cd99的组合物和方法 Download PDF

Info

Publication number
CN107614531A
CN107614531A CN201680029228.0A CN201680029228A CN107614531A CN 107614531 A CN107614531 A CN 107614531A CN 201680029228 A CN201680029228 A CN 201680029228A CN 107614531 A CN107614531 A CN 107614531A
Authority
CN
China
Prior art keywords
antibody
cell
marrow
patient
lymphoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680029228.0A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯托弗·Y·派克
斯蒂芬·S·S·钟
蒙却·塔瓦阔利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN107614531A publication Critical patent/CN107614531A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201680029228.0A 2015-03-18 2016-03-18 在造血和淋巴恶性肿瘤中靶向cd99的组合物和方法 Pending CN107614531A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135119P 2015-03-18 2015-03-18
US62/135,119 2015-03-18
PCT/US2016/023303 WO2016149682A2 (fr) 2015-03-18 2016-03-18 Compositions et procédés de ciblage de cd99 dans les malignités lymphoïdes et hématopoïétiques

Publications (1)

Publication Number Publication Date
CN107614531A true CN107614531A (zh) 2018-01-19

Family

ID=56919925

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680029228.0A Pending CN107614531A (zh) 2015-03-18 2016-03-18 在造血和淋巴恶性肿瘤中靶向cd99的组合物和方法

Country Status (9)

Country Link
EP (1) EP3271399A4 (fr)
JP (1) JP2018511311A (fr)
KR (1) KR20170136535A (fr)
CN (1) CN107614531A (fr)
AU (1) AU2016232719A1 (fr)
BR (1) BR112017019856A2 (fr)
CA (1) CA2980038A1 (fr)
MX (1) MX2017011882A (fr)
WO (1) WO2016149682A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112040957A (zh) * 2018-01-08 2020-12-04 H·李·莫菲特癌症中心和研究所公司 靶向表达cd99的癌症的组合物和方法
IT201800005991A1 (it) * 2018-06-04 2019-12-04 Complesso anticorpale ed usi derivati
WO2019234580A1 (fr) * 2018-06-04 2019-12-12 Diatheva S.R.L. Dianticorps anti-cd99 ou anticorps igg et utilisations correspondantes

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
CN101437539A (zh) * 2005-07-05 2009-05-20 康奈尔研究基金会（有限公司） 通过干扰cd99l2阻断白细胞迁出和炎症
WO2011034969A1 (fr) * 2009-09-15 2011-03-24 The Board Of Trustees Of The Leland Stanford Junior University Thérapie par anti-cd47 synergique pour les cancers hématologiques
WO2013116656A1 (fr) * 2012-02-03 2013-08-08 Emory University Compositions immunostimulatrices, particules et applications associées
CN105246912A (zh) * 2012-12-20 2016-01-13 人类起源公司 嵌合抗原受体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024169A1 (fr) * 2004-09-01 2006-03-09 Hemax Genome Inc. Genes de la region pseudoautosomale 1 et leur utilisation dans le diagnostic, le traitement et la prevention de maladies auto-immunes
US20110230372A1 (en) * 2008-11-14 2011-09-22 Stc Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and outcome prediction in pediatric b-precursor acute lymphoblastic leukemia
WO2015069935A1 (fr) * 2013-11-06 2015-05-14 Memorial Sloan-Kettering Cancer Center Compositions et méthodes de traitement des leucémies aiguës myéloblastiques et des syndromes myélodysplasiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
CN101437539A (zh) * 2005-07-05 2009-05-20 康奈尔研究基金会（有限公司） 通过干扰cd99l2阻断白细胞迁出和炎症
WO2011034969A1 (fr) * 2009-09-15 2011-03-24 The Board Of Trustees Of The Leland Stanford Junior University Thérapie par anti-cd47 synergique pour les cancers hématologiques
WO2013116656A1 (fr) * 2012-02-03 2013-08-08 Emory University Compositions immunostimulatrices, particules et applications associées
CN105246912A (zh) * 2012-12-20 2016-01-13 人类起源公司 嵌合抗原受体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KYEONG CHEONJUNG等: "The CD99 signal enhances Fas-mediated apoptosis in the human leukemic cell line, Jurkat", 《FEBS LETTERS》 *
STEPHEN S. CHUNG等: "CD99 Is a Therapeutic Target on Disease Initiating Stem Cells in Acute Myeloid Leukemia and the Myelodysplastic Syndromes", 《BLOOD》 *
STEPHEN S. CHUNG等: "CD99 Is a Therapeutic Target On Disease Stem Cells In Acute Myeloid Leukemia and The Myelodysplastic Syndromes", 《BLOOD》 *
林丽萍等: "细胞黏附分子CD99与肿瘤关系的研究进展", 《第二军医大学学报》 *
汪春年等: "LAT和CD99在T淋巴母细胞淋巴瘤中的表达及意义", 《临床与实验病理学杂志》 *

Also Published As

Publication number Publication date
CA2980038A1 (fr) 2016-09-22
JP2018511311A (ja) 2018-04-26
EP3271399A4 (fr) 2019-03-20
WO2016149682A2 (fr) 2016-09-22
BR112017019856A2 (pt) 2018-05-29
MX2017011882A (es) 2018-04-20
AU2016232719A1 (en) 2017-10-12
WO2016149682A3 (fr) 2017-01-26
KR20170136535A (ko) 2017-12-11
EP3271399A2 (fr) 2018-01-24

Similar Documents

Publication Publication Date Title
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
JP2021193150A (ja) 小細胞肺癌に対する標的療法
CN107810011A (zh) 使用抗ox40抗体治疗癌症的方法
US20220273722A1 (en) Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment
US20160272720A1 (en) Compositions and Methods for the Treatment of Acute Myeloid Leukemias and Myelodysplastic Syndromes
CN110248678A (zh) 调节car-t细胞的方法
CN110290807A (zh) 确定car-t细胞给药的方法
Si Lim et al. Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B‐cell acute lymphoblastic leukemia
CN107614531A (zh) 在造血和淋巴恶性肿瘤中靶向cd99的组合物和方法
US20220362299A1 (en) Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibiton techniques
US20220389106A1 (en) Anti-epha10 antibodies and methods of use thereof
CN114401990A (zh) 用于调节髓系细胞炎性表型的抗psgl-1组合物和方法及其用途
WO2023159136A2 (fr) Modification d'épitope de récepteurs de surface cellulaire
US20240093304A1 (en) Alk fusion genes and uses thereof
JP2022505158A (ja) Ｎｋエンゲージャー分子およびその使用方法
CN115372611B (zh) Cd16+成纤维细胞在诊断、预防和治疗单克隆抗体耐药乳腺癌中的应用
US20220363766A1 (en) Compositions and methods for treating cytotoxic t cell resistant tumors
EP4137154A1 (fr) Traitement thérapeutique de leucémies lymphoblastiques aiguës à lymphocytes t avec un anticorps monoclonal reconnaissant le récepteur pre-tcr
US20230287129A1 (en) Siglec-6-binding polypeptides
WO2023163956A2 (fr) Inhibiteurs de kir3dl3 et agents d'activation de cellules immunitaires
EP4320153A1 (fr) Méthodes de traitement d'un lymphome anaplasique à grandes cellules
KR20240012413A (ko) 폐암 치료를 위한 조성물 및 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180119

WD01 Invention patent application deemed withdrawn after publication